BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7532766)

  • 1. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group.
    Taylor PR; Reid MM; Stark AN; Bown N; Hamilton PJ; Proctor SJ
    Leukemia; 1995 Feb; 9(2):231-7. PubMed ID: 7532766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
    Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
    Doubek M; Palasek I; Brychtova Y; Buchtova I; Mayer J
    Neoplasma; 2005; 52(5):411-4. PubMed ID: 16151586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
    Mandelli F; Petti MC; Lo Coco F
    Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
    Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the impact of allogenic transplant in first remission on an unselected population of patients with acute myeloid leukaemia aged 15-55 years. The Northern Regional Haematology Group.
    Proctor SJ; Taylor PR; Stark A; Carey PJ; Bown N; Hamilton PJ; Reid MM
    Leukemia; 1995 Jul; 9(7):1246-51. PubMed ID: 7630200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S
    Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
    Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
    Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
    Koistinen P; Räty R; Itälä M; Jantunen E; Koivunen E; Nousiainen T; Pelliniemi TT; Remes K; Ruutu T; Savolainen ER; Siitonen T; Silvennoinen R; Volin L; Elonen E;
    Eur J Haematol; 2007 Jun; 78(6):477-86. PubMed ID: 17391337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
    Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
    Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission.
    Ferrara F; Morabito F; Latagliata R; Martino B; Annunziata M; Oliva E; Schiavone EM; Pollio F; Palmieri S; Gianfaldoni G; Leoni F
    Haematologica; 2001 Aug; 86(8):814-20. PubMed ID: 11522537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG).
    Wedding U; Bokemeyer C; Meran JG; ; ;
    Onkologie; 2004 Feb; 27(1):72-82. PubMed ID: 15007253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.